

Background

- Few men who have sex with men (MSM) are currently using daily oral (DO) HIV pre-exposure prophylaxis (PrEP)
- Newer options, such as on-demand (OD) oral and long-acting injectable (LA) PrEP may improve uptake

OBJECTIVE: Preferences for starting various PrEP options were examined among a US nationwide online convenience sample of MSM

Methods

Recruitment

- September 2021 to February 2022
- Online recruitment through banner ads on social media, sex-seeking and gay interest websites and apps



Eligibility

- 15 years of age or older
- Cisgender male
- Had oral or anal sex with a man at least once in the past OR identify as gay/bisexual (15-17yo only)
- US residence


Additional analytic criteria

- Oral or anal sex with another man in the past 12 months
- No self-report of prior HIV diagnosis

Measures

- Scenario based preferences – after brief explanation of PrEP option “If [PrEP option] were available from your local doctor and you could access it for free, would you go to your doctor in the next month to start [PrEP option]?”
- Rank preferences if would start multiple
- If current DO user, framed as “would you switch”

Example LA-PrEP explanation



Statistical Analysis

Willingness to start LA-PrEP explored with multivariable logistic regression with predicted margins approach, for age, race/ethnicity, insurance and heard of LA-PrEP. Adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) reported.

Results

Figure 1. Willingness to start PrEP options among men who have sex with men who are not currently taking daily oral PrEP, AMIS, 2021-2022






Figure 2. Willingness to start PrEP options among men who have sex with men who are currently taking daily oral PrEP, AMIS, 2021-2022



Willingness to Use Injectable HIV Pre-exposure Prophylaxis among United States Men who have Sex with Men, American Men's Internet Survey, 2021



No significant difference by age group. See abstract for Table with full findings.

Key Information

- 2021-2022 online nationwide survey with MSM about their preferences for different PrEP options
 - Daily oral (DO)
 - On-demand (OD)
 - Long-acting injectable (LA)
- Among those not currently taking DO-PrEP
 - 50% would start some type of PrEP
 - OD-PrEP was ranked first
 - 73% of those would start multiple types of PrEP
 - LA-PrEP was ranked first among people who chose multiple PrEP options
- Among those currently taking DO-PrEP
 - 58% would switch to something else
 - LA-PrEP was ranked first
- Willingness to start LA-PrEP was **higher** among
 - Hispanic/Latino MSM not currently using DO-PrEP
 - Prior awareness of LA-PrEP, regardless of DO-PrEP use

- Willingness to start LA-PrEP was **lower** among
 - Other/multiple insured MSM not currently using DO-PrEP

Discussion and Conclusions

- There is substantial interest in new PrEP options
- Current DO-PrEP users appear to be more aware of and interested in LA-PrEP
- Although OD-PrEP may be favored by those who are not taking PrEP, most selected multiple options and preferred LA-PrEP
- There are few disparities in LA-PrEP interest
- Increasing awareness of LA-PrEP may bolster interest in its use.
- These findings highlight the potential role that newer PrEP options will play in community uptake of PrEP and can inform patient-provider decisions about which PrEP options to consider

Connect with Us



Travis.Sanchez@Emory.edu or +1-404-727-8403

AMIS@Emory.edu or <https://EmoryAMIS.org>

@AmericanMensInternetSurvey



This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.